Sirnaomics Ltd. Completes Partial Share Subscription to Boost Drug Development
I'm PortAI, I can summarize articles.
Sirnaomics Ltd. completed a partial share subscription, issuing 1,003,700 new shares at HK$12.00 each, raising HK$12.0 million for drug development. The remaining shares were mutually terminated without affecting operations. The funds will enhance RNAi therapeutics. Current analyst rating is Hold with a HK$7.50 target. Sirnaomics focuses on RNAi therapeutics, including STP705 and STP122G. Market cap is HK$736.1M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments